Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Research Council grant · Running

MACROMUNO Novel macrodiolide Immunosuppressants

Coordinator
Aarhus Universitet, Denmark
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213966

What the project is doing

In the project's own words, from its summary on CORDIS.

Several major unmet medical needs, such as autoimmune disorders and neuroinflammatory conditions, are characterized by aberrant Type-1 interferon production, suggesting that new drugs that specifically target this central inflammatory signalling axis could provide significant value for patients and for society. In this project, we will develop the foundation for future commercial exploitation of a class of novel macrocyclic immunosuppressants which has been shown to possess unprecedented broad inhibitory activities against several innate immunological pathways that converge on the transcription factor IRF3 linked to interferon production.

Based on diverse preliminary data that span both cellular biology and chemical synthesis strategies, the planned work is aimed at securing a strong IP-position by providing novel structure-activity relation data on relevant cellular activities linked to IRF3-activity. The project will proceed to identify potential compound leads with favourable pharmacokinetic properties to be pushed forward for future in vivo experiments.

The primary focus will be on ability to permeate the blood-brain-barrier (to address major neuroinflammatory conditions) and on achieving good plasma stability. Alongside the concrete experimental tasks and strengthening of the IP-position, a broader business plan and associated funding strategy will be prepared. This involves engagement of key future stakeholders and establishment of an advisory board. Overall, the planned activities serve to make the project ready for a pre-seed investment or acceptance into an biotech-accelerator program following completion of the ERC-PoC project.

Who is involved

OrganisationCityCountryRole
Aarhus UniversitetAarhus CDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI